Navigation Links
Cardica to Announce Fiscal 2008 Fourth Quarter and Year End Financial Results on Tuesday, August 5, 2008
Date:7/29/2008

ord-protected event management site.

About Cardica, Inc.

Cardica is a leading provider of automated anastomosis systems for coronary artery bypass graft (CABG) surgery. By replacing hand-sewn sutures with easy-to-use automated systems, Cardica's products provide cardiovascular surgeons with rapid, reliable and consistently reproducible anastomoses, or connections of blood vessels, often considered the most critical aspect of the CABG procedure. Cardica's C-Port(R) Distal Anastomosis Systems are marketed in Europe and the United States. The PAS-Port(R) Proximal Anastomosis System is marketed in Europe and Japan, and Cardica has submitted a 510(k) premarket notification for clearance to market the PAS-Port system in the United States. Cardica also is developing additional devices with Cook Medical to facilitate vascular closure and other surgical procedures.


'/>"/>
SOURCE Cardica, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Cardica Names Frederick Bauer Vice President of Operations
2. Renowned Leader and Educator in Robotic Cardiac Bypass Surgery Leverages Cardicas C-Port(R) Flex-A(R) Anastomosis System in His Practice and to Educate Cardiothoracic Surgeons
3. Cardica, Intuitive Surgical, MAQUET Cardiovascular and Transonic to Host Innovations in Revascularization Symposium
4. Cardica to Announce Fiscal 2008 Third Quarter Financial Results on Tuesday, April 29, 2008
5. Cardicas C-Port Anastomosis Systems Facilitate Beating Heart Bypass Surgery in Study
6. Cardicas C-Port Anastomosis Systems for Coronary Artery Bypass Graft Procedures to be Used to Train Cardiothoracic Surgeons at Society of Thoracic Surgeons (STS) University
7. Cardica to Announce Fiscal 2008 Second Quarter Financial Results on Thursday, January 24, 2008
8. Cardica Announces Exercise of Over-Allotment Option
9. Cardica Announces Live Webcast Demonstrating Breakthrough Device to Facilitate Beating Heart and Robotic Coronary Revascularization Surgery
10. Cardica Announces Pricing of $34.7 Million Public Offering of Common Stock
11. Cardica Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Virginia Business Coalition on Health Issues Statement of Support for Hospital Improvement 2Health News:Virginia Business Coalition on Health Issues Statement of Support for Hospital Improvement 3Health News:Study Suggests Need for More Aggressive Outpatient Monitoring of Patients' Hearts When Cause of Stroke is Unclear 2Health News:Study Suggests Need for More Aggressive Outpatient Monitoring of Patients' Hearts When Cause of Stroke is Unclear 3Health News:Zimbabwean Health Workers Call For Crisis Response 2Health News:Zimbabwean Health Workers Call For Crisis Response 3Health News:Bloomberg School awards Goodermote Humanitarian Award to Soledad O'Brien 2Health News:Interim HealthCare Recognizes Outstanding Franchisees at National Clinical Symposium 2Health News:Interim HealthCare Recognizes Outstanding Franchisees at National Clinical Symposium 3Health News:Lilly and International Council of Nurses Win Partnership Award From the U.S. Chamber of Commerce Business Civic Leadership Center 2Health News:Lilly and International Council of Nurses Win Partnership Award From the U.S. Chamber of Commerce Business Civic Leadership Center 3
Breaking Medicine Technology:Vivakor Announces New Acquisition Strategy 2Millstone Medical Outsourcing Appoints New Leadership of Memphis Facility 2Indiana Blood Center Taps tw telecom for Data, Internet and IP Telephony Services 2PSI Commits to Expanding HIV Prevention at Clinton Global Initiative 58120 1PSI Commits to Expanding HIV Prevention at Clinton Global Initiative 58120 2PSI Commits to Expanding HIV Prevention at Clinton Global Initiative 58120 3Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression Free Survival in Patients With Advanced Breast Cancer in P 58118 1Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression Free Survival in Patients With Advanced Breast Cancer in P 58118 2Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression Free Survival in Patients With Advanced Breast Cancer in P 58118 3Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression Free Survival in Patients With Advanced Breast Cancer in P 58118 4Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression Free Survival in Patients With Advanced Breast Cancer in P 58118 5Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression Free Survival in Patients With Advanced Breast Cancer in P 58118 6Sorafenib significantly improves the length of time before breast cancer worsens 58117 1Sorafenib significantly improves the length of time before breast cancer worsens 58117 2